Full Title
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient SettingPurpose
Epcoritamab is a drug used to treat lymphoma. The first full dose is typically given in the hospital, which can involve an overnight stay. In this study, researchers want to see if epcoritamab can be safely given on an outpatient basis.
The people in this study have classic follicular lymphoma (cFL) or diffuse large B-cell lymphoma (DLBCL). Their lymphoma keeps growing or came back even after treatment.
Epcoritamab is a bispecific antibody. It is designed to bind to two different proteins at once: one on cancer cells and another on immune cells. It strengthens the immune system’s ability to fight cancer cells. Epcoritamab is given as a subcutaneous (under the skin) injection.
Who Can Join
To join this study, there are a few conditions. You must:
- Have cFL or DLBCL that keeps growing or came back after treatment.
- Have recovered from the serious side effects of previous anti-cancer therapies.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Alexander Boardman’s office at 646-608-4309.